Ocugen, INC 10-K annual reports

Ocugen, Inc. reported increased net losses and a going concern warning for 2025, despite advancing its gene therapy pipeline with positive clinical data and regulatory milestones.

Ocugen's 2024 10-K filing highlights progress in gene therapy programs, vaccine development, and provides a detailed overview of the company's financial condition and future strategies.

Ocugen has filed an amendment to its annual report to include information on directors, executive compensation, and corporate governance, as the company will not file its definitive proxy statement within the required timeframe.

Ocugen, Inc. released its 10-K filing, which included a restatement of previous financials and updates on its pipeline, including a Phase 3 trial initiation for OCU400.